A5091580359- Bone health and treatments
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Chemokine receptors and signaling
- DNA Repair Mechanisms
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
Tsinghua University
2023-2024
Abstract The majority of patients with late-stage breast cancer develop distal bone metastases. microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation...
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S2 is related to Figure 5 (Olaparib-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Supplemental Figures 1-7</p>
<p>Supplemental Figures 1-7</p>
<p>Supplementary Video S2 is related to Figure 5 (Olaparib-only group).</p>